Vivani Medical to Present at the American Association of Pharmaceutical Scientists’ “Beyond GLP1s: Where the Science will Take Business Next” Virtual Workshop

Core Viewpoint - Vivani Medical, Inc. is advancing its innovative miniature drug implants aimed at improving patient adherence in chronic disease treatment, particularly in the GLP-1 drug class [1][4][5] Company Overview - Vivani Medical, Inc. is a clinical-stage biopharmaceutical company focused on developing ultra long-acting drug implants using its proprietary NanoPortal™ technology [1][4] - The company's lead programs include NPM-115 (exenatide implant) for weight management and NPM-139 (semaglutide implant) for chronic weight management, both designed for infrequent administration [4] Upcoming Events - CEO Adam Mendelsohn will present at the AAPS workshop on May 14, 2025, discussing advances in drug delivery and patient adherence [2][3] - The presentation will focus on the company's lead program, NPM-115, with results from the LIBERATE-1™ study expected this year [2] Industry Context - Medication non-adherence affects approximately 50% of patients, contributing to over $500 billion in avoidable healthcare costs and 125,000 preventable deaths annually in the U.S. [5] - The current GLP-1 landscape includes over 50 new molecular entities in clinical development, highlighting the competitive environment in which Vivani operates [5]